Clinical Trials Logo

Filter by:
NCT ID: NCT04965467 Withdrawn - Fabry Disease Clinical Trials

Fabry Aim Children Early (ACE) Project

Start date: July 27, 2021
Phase:
Study type: Observational

The purpose of this study is to assess the frequency of Fabry disease in children with early symptoms.

NCT ID: NCT04958967 Withdrawn - NSCLC Clinical Trials

Phase Ib Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation

Start date: October 1, 2021
Phase: Phase 1
Study type: Interventional

This is a phase 1 multi-center clinical study. To explore the efficacy and safety of Furmonertinib Mesilate at different doses in locally advanced or metastatic NSCLC patients with EGFR exon 20 insertion mutation. The study plans to enroll 20subjects, including 20 treated patients aThe subjects will receive Furmonertinib Mesilate 240 mg/day or 160mg/day until disease progression, death or intolerability. The primary endpoint is Overall Response Rate (ORR) as Assessed by the Independent Review Committee (IRC); the secondary study endpoints include ORR( Assessed by the Investigator),DCR,DOR,DpR,PFS,OS,CNS ORR( Assessed by the Independent Review Committee) In addition, the peripheral blood ctDNA will be collected and analyzed in this study

NCT ID: NCT04947371 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Adjuvant Therapy With Anlotinib for HCC

Start date: December 15, 2018
Phase: Phase 2
Study type: Interventional

Patients with high risk of disease recurrence after curative resection for hepatocellular carcinoma (HCC) deserve active intervention. However, there's limited treatment choice for these patients. Anlotinib hydrochloride, a multitarget tyrosine kinase inhibitor for both tumor angiogenesis and proliferative signaling in cancer cells, is approved in China for the 3rd line treatment of advanced non-small cell lung cancer. In the current study, we are to evaluate the safety and effects of adjuvant anlotinib therapy for the patients who underwent curative resection for HCC with high risk of tumor recurrence, which is defined by Shanghai Score (Sun, et al. Chin Med J (Engl) 2017).

NCT ID: NCT04927988 Withdrawn - Clinical trials for Placenta Accreta Spectrum

Blood Components Changes by Using of Ringer's Lactated as Detergent In Autologous Blood Cell Transfusion

Start date: October 2021
Phase: N/A
Study type: Interventional

Placenta accreta spectrum (PAS) disorders are associated with increased maternal morbidity and mortality related to life-threatening hemorrhage, and greater potential need for blood transfusion. Clinical evidences have confirmed that the use of autologous blood cell transfusion is safe and effective for patients with obstetric haemorrhage. Normal saline is the solution recommended for red cell washing, administration and salvage. However, there is growing concern that normal saline is more toxic than balanced, buffered crystalloids such as Lactated Ringer's and Plasma-Lyte. The purpose of this study is to evaluate the blood components using of Ringer's Lactated by a prospective, single-center, open, and single-arm clinical trial.

NCT ID: NCT04921696 Withdrawn - Anemia Clinical Trials

Association of Red Blood Cell Transfusion, Anemia, and Necrotizing Enterocolitis

Start date: July 1, 2021
Phase:
Study type: Observational

Necrotizing enterocolitis (NEC) is a leading cause of mortality among preterm infants.The pathogenesis of NEC remains unclear with conflicting data regarding the role of red blood cell (RBC) transfusion and anemia. A meta-analysis of retrospective studies demonstrated an association between exposure to RBC transfusion and NEC(adjusted odds ratio, 2.0 [95% confidence interval, 1.6-2.5]). However, recent observational studies have found no association between RBC transfusion and NEC or have found RBC transfusion to be protective.

NCT ID: NCT04894682 Withdrawn - Lung Cancer Clinical Trials

Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor

CoVac-Lung
Start date: May 4, 2021
Phase:
Study type: Observational

The objective of this study is to assess the inoculation-related symptoms and long-term effects of COVID-19 vaccines in patients with lung cancer or pulmonary nodules in a real-world setting. The investigators aim to provide high-quality evidence for the COVID-19 vaccines in cancer/pre-cancer patients, and to address their concern about the safety profile of the newly developed vaccines.

NCT ID: NCT04890379 Withdrawn - Clinical trials for Intracerebral Hemorrhage

Dimethyl Fumarate for the Treatment of Intracerebral Hemorrhage

Start date: June 1, 2021
Phase: Phase 2
Study type: Interventional

The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in alleviating PHE and neurologic deficits in patients with ICH.

NCT ID: NCT04872127 Withdrawn - Stroke Clinical Trials

Distal Versus Proximal Protection on Cerebral Microembolization During High-risk Carotid Artery Stenting

MOSCASH
Start date: May 1, 2021
Phase: N/A
Study type: Interventional

A multicenter, prospective, outcome-assessor-blinded, randomized controlled trial study (MOSCASH) is designed to compare the efficiency of distal and proximal embolism protection devices during carotid angioplasty and stenting (CAS) procedure of patients with high-intensity signal in the plaque on the time-of-flight magnetic resonance angiography(TOF-MRA) .

NCT ID: NCT04865146 Withdrawn - Hip Fractures Clinical Trials

A Study to Evaluate the Safety and Effectiveness of TRIGEN™ INTERTAN™ (10S Models)

Start date: June 23, 2022
Phase:
Study type: Observational

This is a post-market study to evaluate the revision rate of femoral fractures, treated with INTERTAN 10S Nails at one-year post-operation. The study will enroll Approximately 180 subjects with femoral fractures, Approximately 7 sites are involved. The study duration will be Approximately 36 months (6 months start-up, 1 year enrollment, 1 year follow-up, 6 months closeout/study report).

NCT ID: NCT04860817 Withdrawn - Clinical trials for T-cell Acute Lymphoblastic Leukemia

A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL

Start date: December 1, 2021
Phase: Early Phase 1
Study type: Interventional

T cells are a type of immune cell. Like other cells of the body, T Cells can develop cancer. T cell cancers mainly include T cell leukaemia and T cell lymphoma, both of which have a relatively poor prognosis. Currently, patients with relapsed/refractory type (the name given to cancer that reappears or grows again after a period of no changes or signs of cancer) of this leukaemia or lymphoma have limited choices for treatment. CAR-T cells are immune cells that are engineered to target specific cell markers. For example, CAR-T cells targeting the marker CD19 have shown great effectiveness in the treatment of B cell tumors that carry this marker. Here investigators construct a new universal CAR-T design targeting CD7 which is found on the cells of relapsed/refractory type T cell leukaemia and lymphoma and hope to test its safety and efficiency in the treatment of relapsed/refractory type T cell leukaemia and lymphoma.